Format

Send to

Choose Destination
J Dermatolog Treat. 2017 Dec;28(8):774-779. doi: 10.1080/09546634.2017.1328938. Epub 2017 May 24.

A new topical panthenol-containing emollient for maintenance treatment of childhood atopic dermatitis: results from a multicenter prospective study.

Author information

1
a Bayer Consumer Care AG , Basel , Switzerland.
2
b Kinder & Jugendmedizinpraxis , Neumünster , Germany.
3
c Proinnovera GmbH , Münster , Germany.

Abstract

PURPOSE:

A study was conducted with a new topical panthenol-containing emollient (NTP-CE) to investigate the efficacy and safety of a 3-month maintenance treatment in infants and children with stabilized mild atopic dermatitis (AD).

METHODS:

After the stabilization phase (up to 2 months) using a corticosteroid-free topical medical device, 108 subjects (aged 2-49 months) with a SCORing AD (SCORAD) on the target area of <5, were randomized to receive NTP-CE (N = 52) or reference emollient (N = 56) twice-daily for ∼3 months. SCORAD scores, occurrence of flares, and tolerability were assessed at regular intervals.

RESULTS:

In both groups, local SCORAD decreased during the study with a mean change from baseline (=end of stabilization phase) of -1.2 ± 1.3 (NTP-CE) and -1.0 ± 1.9. Kaplan-Meier analysis provided success rates (i.e. proportion of subjects without flares at study end) of 96 and 77% for the NTP-CE and reference group, respectively (p =.083, log-rank test). Mean time to flare-up was 47 days (range: 29-65) in the NTP CE group and 50 days (6-100). Study products were well tolerated.

CONCLUSIONS:

Our results indicate that NTP-CE is efficacious and safe when used for maintenance treatment of mild childhood AD.

KEYWORDS:

Emollient; atopic dermatitis; children; efficacy; panthenol

PMID:
28511614
DOI:
10.1080/09546634.2017.1328938
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center